Title: Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Authors: Delforge, Michel ×
Bladé, Joan
Dimopoulos, Meletios A
Facon, Thierry
Kropff, Martin
Ludwig, Heinz
Palumbo, Antonio
Van Damme, Philip
San-Miguel, Jesús F
Sonneveld, Pieter #
Issue Date: Nov-2010
Publisher: Lancet Pub. Group
Series Title: The Lancet Oncology vol:11 issue:11 pages:1086-1095
Abstract: Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has substantially improved outcomes for patients with multiple myeloma. As a result, these drugs have become cornerstones of current antimyeloma treatment regimens. However, after several years of clinical experience it has become apparent that peripheral neuropathy is the most common and potentially disabling non-haematological side-effect associated with thalidomide and bortezomib. Maximising treatment benefit while preserving quality of life therefore requires a careful balance between achieving optimum activity and minimising toxicity, including neuropathy, to further enhance efficacy. In this review, we discuss all aspects of drug-induced peripheral neuropathy in myeloma, with a particular focus on thalidomide and bortezomib.
ISSN: 1470-2045
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hematology Section (-)
Research Group Experimental Neurology
Laboratory for Neurobiology (Vesalius Research Center)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Delforge_TLO_final.txt Published 60KbTextView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science